SCHEMBL10260271

SCHEMBL10260271

CC[C@H]1O[C@@H](n2cnc(C)nc2=O)C(C)[C@H]1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
DNMT1 P26358 2/20 0.43
MTOR P42345 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TP53 P04637 2/20 0.43
GMNN O75496 1/20 0.43
NFKB1 P19838 1/20 0.43
THPO P40225 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
BLM P54132 1/20 0.43
HBB P68871 1/20 0.43
PMP22 Q01453 1/20 0.43
ADRB1 P08588 1/20 0.34
THRB P10828 1/20 0.30
MDM2 Q00987 1/20 0.30
NCOA1 Q15788 1/20 0.30
NCOA3 Q9Y6Q9 1/20 0.30
MAPT P10636 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17772525 0.88 DNMT1 (0.49) LMNADNMT1MTORALDH1A1TP53
SCHEMBL10260614 0.88 DNMT1 (0.57) LMNADNMT1MTORALDH1A1TP53
SCHEMBL13485203 0.88 DNMT1 (0.57) LMNADNMT1MTORALDH1A1TP53
SCHEMBL10267488 0.88 DNMT1 (0.57) LMNADNMT1MTORALDH1A1TP53
SCHEMBL10261334 0.76 DNMT1 (0.48) LMNADNMT1MTORALDH1A1TP53
SCHEMBL10033349 0.75 TK1 (0.32) MAPT
SCHEMBL10024704 0.74 LMNA (0.52) LMNADNMT1MTORALDH1A1TP53
SCHEMBL14549613 0.74 LMNA (0.52) LMNADNMT1MTORALDH1A1TP53
SCHEMBL13151577 0.74 LMNA (0.40) LMNAMTORTHRBMDM2NCOA1
SCHEMBL13672354 0.74 LMNA (0.40) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8212021-B2 Process for making 5-azacytosine nucleosides and their derivatives SCINOPHARM TAIWAN, LTD. (TW) 2012-07-03 US disclosed
US-20100036112-A1 Process for Making 5-Azacytosine Nucleosides and Their Derivatives SCINOPHARM TAIWAN LTD. 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036112-A1 Process for Making 5-Azacytosine Nucleosides and Their Derivatives DCTD, DUT, DPYD LMNA 2350/4885DNMT1 14/4885MTOR 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.